Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion

Overview of attention for article published in Frontiers in oncology, March 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 9,096 followers.

Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring <em>ALK-IGFBP5</em> fusion #lymphoma #lymsm https://t.co/OVJKTMJSgL

10 Apr 2023

Reply Repost Favourite

Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion https://t.co/lVOMzm8wzw #sarcoma #leiomyosarcoma

10 Apr 2023

Reply Repost Favourite

New research: Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion: Background An inflammatory myofibroblastic tumor (IMT) is a… https://t.c

02 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.